Recon: WHO launches COVID-19 IP pool with 30 countries; Sanofi vaccine chief heads to Ipsen

• Administration initially dispensed scarce covid-19 drug to some hospitals that didn’t need it (Washington Post)
• Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows (STAT) (Endpoints)
• US hospitals slash use of drug championed by Trump as coronavirus treatment (Reuters)
• US FDA approves Eli Lilly's diagnostic agent for Alzheimer's disease (Reuters) (FDA) (Press)
• Minerva's schizophrenia drug misses main goal in study; shares tumble (Reuters)
• Watchdog groups want Trump's coronavirus vaccine czar to disclose all pharma ties (The Hill)
• US senators offer bill to prepare for the next pandemic (Reuters)

• Thirty countries launch alliance to share COVID-19 tools (Reuters)
• Pharma leaders shoot down WHO voluntary pool for patent rights on Covid-19 products (STAT) (PMLive)
• EU launches new COVID-19 fundraising to address concerns over equal access (Reuters)
• Sanofi's head of vaccines leaves for smaller competitor Ipsen (Reuters) (Endpoints 1, 2)
• Pakistan drug firm to import potential COVID-19 treatment from Bangladesh (Reuters)
• Sun Pharma to test pancreatitis drug in COVID-19 patients in India (Reuters)
• South Korea seeks to import anti-viral remdesivir as new coronavirus cases emerge (Reuters)
• AstraZeneca's top-selling drug slows early-stage lung cancer - trial (Reuters) (STAT) (Endpoints)
• Takeda gets EU green light to keep bowel drug after Shire buy (Reuters) (Fierce) (Endpoints) (Press)
• Germany pauses anti-malaria drug study for COVID-19: Spiegel (Reuters)
• Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID-19 (EMA)

• Scientists Question Validity of Major Hydroxychloroquine Study (NYTimes)
• COVID-19: reminder of the risks of chloroquine and hydroxychloroquine (EMA)
• Rising ICU bed use 'a big red flag' (Politico)
• FDA authorizes Quest’s coronavirus test with at-home sample collection; shares rise (CNBC)
• C.D.C. Recommends Sweeping Changes to American Offices (NYTimes)
• Cancer, coronavirus are a dangerous mix, new studies find (NBC)
• Coronavirus (COVID-19) Update: Daily Roundup May 28, 2020 (FDA)
• Facing vial shortage, pharmas explore workarounds for coronavirus vaccines (BioPharmaDive)

• Bacteria are widespread in tumors, forming distinct populations depending on the cancer type (STAT)
• AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer (Endpoints)
• US FDA Office Of New Drugs Has New Deputy Director In Thanh Hai (Pink Sheet)
• A Senator From Arizona Emerges As A Pharma Favorite (KHN)
• Ironwood, AbbVie kick delayed-release Linzess formulation to the curb after trial failure (Endpoints)
• After starring at ASH last fall, Gilead’s new Forty Seven crew colors in more promising data for magrolimab at ASCO (Endpoints)
• ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer (Fierce) (Endpoints)
• ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients (Fierce)
• As tislelizumab gains traction in China, BeiGene pulls the curtain on NSCLC data supporting the PD-1 drug (Endpoints)
• Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma (Endpoints)
• Designer antibodies fight cancer by tethering immune cells to tumor cells (Science)
• Kura flashes positive HRAS data on once-failed J&J drug (Endpoints)
• Sierra Oncology brings on former Aimmune CEO to the helm; Flagship woos ex-Novartis exec Fabrice Chouraqui (Endpoints)
• For Opioid Users, Pandemic Means New Dangers, But Also New Treatment Options (NPR)
• FDA Accepts Fresenius Kabi Pegfilgrastim Biosimilar Candidate for Review (Big Molecule Watch)
• Roche Seeks Speedy EMA Review For SMA Drug Risdiplam (Pink Sheet)
• CVS, Nuro to test driverless prescription delivery in Houston area (Reuters)
• Amgen Presents New AMG 510 Clinical Data Across Multiple Solid Tumors During ASCO20 Virtual Scientific Program (Press)
• Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML (Press)
• Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS (Press)
• Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery (Press)
• Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time (Press)
• Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer (Press)

• Four deaths trigger Class I recall for Medtronic's HeartWare implant (MedtechDive) (FDA)
• How tariffs ravaged the COVID-19 medical supply chain (Supply Chain Dive)

• FDA Asks Full DC Circ. To Undo Eagle's Orphan Drug Win (Law360)
• Pandemic upends state plans to expand health insurance (Politico)
• Drug and medical device highlights 2019: Helping you maintain and improve your health (Health Canada)
• Notice advising of NCEs to be included in the June 2020 Poisons Standard, May 2020 (TGA)
• TGA stakeholder survey 2019 (TGA)
• TGA initiates court proceedings against MMS Australia and director Charles Barton for alleged unlawful advertising (TGA)